BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CellCentric Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies CellCentric Ltd.'s drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04068597-2849@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Inobrodib: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Inobrodib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study t
 o Evaluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated p
 rimary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/inobrodib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/inobrodib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772024-2849@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Inobrodib: Phase 3 readout est. (NCT07772024)
DESCRIPTION:Inobrodib\, phase 3\, Multiple Myeloma.\nStudy: Inobrodib\, Pom
 alidomide and Dexamethasone Versus Standard Available Therapy in Relapsed 
 or Refractory Multiple Myeloma\nEstimated primary completion: November 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/inobrodib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07772024
URL:https://assetmemo.bio/drug/inobrodib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096778-2849@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Inobrodib: Phase 2 readout est. (NCT07096778)
DESCRIPTION:Inobrodib\, phase 2\, Multiple Myeloma.\nStudy: Inobrodib\, Pom
 alidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: 1 December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/inobrodib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07096778
URL:https://assetmemo.bio/drug/inobrodib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
